Меню
Набор скоро начнётся NCT06945809

Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)

Без фазы С лечением Aortic Dissection Distal Entry Tear

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: WeFlow-EndoPatch Aortic Endovascular Patch System, Conventional Treatment group.
Кому может быть актуально
Состояния в реестре: Aortic Dissection, Distal Entry Tear. Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Guo&Amp;'s Distal Entry Tear Repair: a Multicenter, Prospective, Superiority, Randomized Controlled Trial of the Novel WeFlow-EndoPatch Aortic Endovascular Patch System

Обзор

A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)

Подробное описание

This study is a multicenter, prospective, superiority, randomized controlled trial about the safety and efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System. It is expected to complete the implantation of 204 patients in 15 centers within 24 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24th month, 36th month, 48th month and 60th month postoperatively.

Вмешательства

  • Устройство WeFlow-EndoPatch Aortic Endovascular Patch System
    The WeFlow-EndoPatch Aortic Endovascular Patch System for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
  • Другое Conventional Treatment group
    Doctors prescribe conventional medicines and regular imaging tests.

Первичные конечные точки

  • Treatment Success Rate [Срок оценки: 12 months]
Вторичные конечные точки (8)
  • Immediate Technical Success in EndoPatch Group [Срок оценки: Immediately after the surgery]
  • Entry Tears Closure Success in EndoPatch Group [Срок оценки: 30 days, 6 months, and 12 months]
  • False Lumen Thrombosis of the Descending Thoracic Aorta [Срок оценки: 30 days, 6 months, and 12 months]
  • True Lumen/False Lumen/Maximum Total Diameter of Descending Thoracic Aorta [Срок оценки: 30 days, 6 months, and 12 months]
  • Device and/or Procedure Related Reinterventions [Срок оценки: 30 days, 6 months, and 12 months]
  • No major adverse events within 30 days after surgery [Срок оценки: Before discharge, 30 days after surgery]
  • Patch Fall-off in EndoPatch Group [Срок оценки: 30 days, 6 months, and 12 months]
  • All-cause Mortality, Aortic Dissection-related Mortality, Serious Adverse Events, and Device-related Adverse Events [Срок оценки: 30 days, 6 months, and 12 months]

Критерии участия

Критерии включения

  • Patients aged 18 to 80 years old, no gender limitation;
  • The patient was diagnosed with chronic aortic dissection after the repair of the main artery dissection, with distal tears required seal;
  • The maximum diameter of the descending thoracic aorta is 3.5-5cm;
  • The number of thoracic descending aorta tears is ≤2, and the maximum diameter of the tears is 2-30 mm;
  • With appropriate artery approaches, endovascular treatment can be performed;
  • Those who can understand the purpose of the trial, voluntarily participate in the study, sign the informed consent form by themselves or their legal representative, and are willing to complete the follow-up according to the protocol requirements.

Критерии исключения

  • Rupture or threatened rupture of aortic dissection;
  • Proximal type I internal leakage after aortic repair;
  • New distal SINE;
  • Abdominal aortic dissection aneurysm diameter ≥5 cm;
  • The edge of the tear from the opening of celiac trunk is<4 mm;
  • The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.);
  • Acute systemic infection;
  • History of myocardial infarction, TIA or cerebral infarction within the past 3 months;
  • Cardiac function Grade IV (NYHA rating) or LVEF \&lt; 30%;
  • Hematological abnormalities: leukopenia (WBC \&lt; 3×10\^9/L), anemia (Hb \&lt; 90 g/L); Coagulation dysfunction, thrombocytopenia (PLT count \&lt; 50×10\^9/L);
  • Renal insufficiency: serum creatinine \&gt; 150 umol/L (or 3.0 mg/dL) and/or advanced kidney disease requiring renal dialysis, as determined by the investigator after thorough analysis;
  • Severe liver insufficiency: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds the normal upper limit by 5 times; Serum total bilirubin (STB) exceeded the normal upper limit by 2 times;
  • Allergic to contrast agents, anesthetics, patchs, and delivery materials;
  • Pregnant or breastfeeding;
  • Participated in clinical trials of other drugs or devices during the same period;
  • Life expectancy is less than 12 months (such as advanced malignant tumors); Investigator judged that not suitable for interventional treatment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

  • Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic a PMID 25173340
  • Hofferberth SC, Nixon IK, Mossop PJ. Aortic false lumen thrombosis induction by embolotherapy (AFTER) following endovascular repair of aortic dissection. J Endovasc Ther. 2012 Aug;19(4):538-45. doi: 10.1583/JEVT-12-3844R.1. PMID 22891838
  • Kolbel T, Tsilimparis N, Wipper S, Larena-Avellaneda A, Diener H, Carpenter SW, Debus ES. TEVAR for chronic aortic dissection - is covering the primary entry tear enough? J Cardiovasc Surg (Torino). 2014 Aug;55(4):519-27. Epub 2014 Jun 11. PMID 24918196
  • Zhu C, Huang B, Zhao J, Ma Y, Yuan D, Yang Y, Xiong F, Wang T. Influence of distal entry tears in acute type B aortic dissection after thoracic endovascular aortic repair. J Vasc Surg. 2017 Aug;66(2):375-385. doi: 10.1016/j.jvs.2016.12.142. Epub 2017 Apr 21. PMID 28438361
  • Wojciechowski J, Znaniecki L, Kaszubowski M, Rogowski J. Late Aortic Remodeling after Endovascular Repair of Complicated Type B Aortic Dissection-TEVAR Protects Only the Covered Segment of Thoracic Aorta. Ann Vasc Surg. 2019 Feb;55:148-156. doi: 10.1016/j.avsg.2018.05.057. Epub 2018 Aug 4. PMID 30081168
  • David TE. Adventitial inversion in the distal anastomosis in surgical treatment of acute DeBakey type I aortic dissection. J Thorac Cardiovasc Surg. 2016 May;151(5):1346-7. doi: 10.1016/j.jtcvs.2016.01.028. Epub 2016 Jan 22. No abstract available. PMID 26874601
  • Nienaber CA, Yuan X, Aboukoura M, Blanke P, Jakob R, Janosi RA, Lovato L, Riambau V, Trebacz J, Trimarchi S, Zipfel B, van den Berg JC; ASSIST study group. Improved Remodeling With TEVAR and Distal Bare-Metal Stent in Acute Complicated Type B Dissection. Ann Thorac Surg. 2020 Nov;110(5):1572-1579. doi: 10.1016/j.athoracsur.2020.02.029. Epub 2020 Mar 20. PMID 32205112

Идентификаторы

NCT: NCT06945809 · WQ11-2402

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗